Analysis of the correlation between serum resistin and the variability of erythropoietin responsiveness in patients with chronic kidney disease

Zhang,Honghao; Li,Xiujiang; Kan,Yanhong; Yang,Fan; Hou,Yue; Du,Yujun

doi:10.3892/etm.2015.2772

Analysis of the correlation between serum resistin and the variability of erythropoietin responsiveness in patients with chronic kidney disease

Authors:
- Honghao Zhang
- Xiujiang Li
- Yanhong Kan
- Fan Yang
- Yue Hou
- Yujun Du
View Affiliations

Affiliations: Department of Nephrology, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China, Intensive Care Unit, Tumor Hospital of Jilin, Changchun, Jilin 130012, P.R. China
Published online on: September 23, 2015 https://doi.org/10.3892/etm.2015.2772
Pages: 1925-1930

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Chronic kidney disease (CKD) is commonly accompanied by inflammation and anemia; however, the pathogenesis of CKD is unclear. Expression of resistin, a cysteine-rich secretory plasma protein, is correlated with the expression of tumor necrosis factor (TNF)-α, interleukin (IL)-6 and lipoprotein-associated phospholipase A2, indicating that resistin may be involved in inflammatory events. In addition, inflammation inhibits the activity of erythropoietin (EPO) and, thus, erythropoiesis. The aim of the present study was to analyze the correlation between serum resistin and the variability of EPO responsiveness in CKD patients. The levels of serum creatinine (SCr), C-reactive protein (CRP), total cholesterol, triglycerides, IL‑6 and serum resistin were measured in the samples obtained from 138 CKD patients and healthy control subjects. The levels of serum resistin in the CKD groups with and without hemodialysis were significantly higher than those observed in the normal control group (P<0.01) and the levels of serum resistin in the hemodialysis CKD group were higher than those observed in the CKD group without dialysis (P<0.01). The levels of serum resistin in patients in the randomly selected CKD group (with hemodialysis) were positively correlated with the duration of dialysis and the levels of SCr and CRP (P<0.05), however, were negatively correlated with the estimated glomerular filtration rate. The EPO resistance index (ERI) was identified to be associated with body mass index and the levels of CRP and resistin; furthermore, EPO reactivity was correlated with the level of resistin and ERI. The levels of serum resistin were correlated with the variability in EPO responsiveness that was observed in the CKD patients. Therefore, the measurement of serum resistin may aid with understanding the mechanisms, clinical diagnosis and treatment of CKD.

View Figures

View References

1	Ota T: Chemokine systems link obesity to insulin resistance. Diabetes Metab J. 37:165–172. 2013. View Article : Google Scholar : PubMed/NCBI
2	Boyraz M, Cekmez F, Karaoğlu A, Cinaz P, Durak M and Bideci A: Relationship of adipokines (adiponectin, resistin and RBP4) with metabolic syndrome components in pubertal obese children. Biomark Med. 7:423–428. 2013. View Article : Google Scholar : PubMed/NCBI
3	Chen XY, Zhang JH, Liu F, Liu HM, Song YY and Liu YL: Association of serum resistin levels with metabolic syndrome and early atherosclerosis in obese Chinese children. J Pediatr Endocrinol Metab. 26:855–860. 2013. View Article : Google Scholar : PubMed/NCBI
4	Drouet L, Bal Dit and Sollier C: Fibrinogen: factor and marker of cardiovascular risk. J Mal Vasc. 27:143–156. 2002.(In French). PubMed/NCBI
5	Kim KH, Lee K, Moon YS and Sul HS: A cysteine-rich adipose tissue-specific secretory factor inhibits adipocyte differentiation. J Biol Chem. 276:11252–11256. 2001. View Article : Google Scholar : PubMed/NCBI
6	Imai E, Horio M, Nitta K, et al: Modification of the Modification of Diet in Renal Disease (MDRD) Study equation for Japan. Am J Kidney Dis. 50:927–937. 2007. View Article : Google Scholar : PubMed/NCBI
7	Steppan CM, Bailey ST, Bhat S, et al: The hormone resistin links obesity to diabetes. Nature. 409:307–312. 2001. View Article : Google Scholar : PubMed/NCBI
8	Ren W, Pan H, Wang P, et al: Clinical analysis of pulmonary infection in hemodialysis patients. Exp Ther Med. 7:1713–1717. 2014.PubMed/NCBI
9	Díez JJ, Iglesias P, Fernández-Reyes MJ, et al: Serum concentrations of leptin, adiponectin and resistin, and their relationship with cardiovascular disease in patients with end-stage renal disease. Clin Endocrinol (Oxf). 62:242–249. 2005. View Article : Google Scholar : PubMed/NCBI
10	Briana DD and Malamitsi-Puchner A: The role of adipocytokines in fetal growth. Ann NY Acad Sci. 1205:82–87. 2010. View Article : Google Scholar : PubMed/NCBI
11	Lago F, Dieguez C, Gómez-Reino J and Gualillo O: The emerging role of adipokines as mediators of inflammation and immune responses. Cytokine Growth Factor Rev. 18:313–325. 2007. View Article : Google Scholar : PubMed/NCBI
12	Papaldo P, Ferretti G, Di Cosimo S, et al: Does granulocyte colony-stimulating factor worsen anemia in early breast cancer patients treated with epirubicin and cyclophosphamide? J Clin Oncol. 24:3048–3055. 2006. View Article : Google Scholar : PubMed/NCBI
13	Anderson PD, Mehta NN, Wolfe ML, et al: Innate immunity modulates adipokines in humans. J Clin Endocrinol Metab. 92:2272–2279. 2007. View Article : Google Scholar : PubMed/NCBI
14	Borissova AM, Djambazova A, Todorov K, Dakovska L, Tankova T and Kirilov G: Effect of erythropoietin on the metabolic state and peripheral insulin sensitivity in diabetic patients on haemodialysis. Nephrol Dial Transplant. 8:931993.PubMed/NCBI
15	Rasic-Milutinovic Z, Perunicic-Pekovic G, Cavala A, Gluvic Z, Bokan L and Stankovic S: The effect of recombinant human erythropoietin treatment on insulin resistance and inflammatory markers in non-diabetic patients on maintenance hemodialysis. Hippokratia. 12:157–161. 2008.PubMed/NCBI
16	National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 39(2 Suppl 1): S1–S266. 2002.PubMed/NCBI
17	Nüsken KD, Kratzsch J, Wienholz V, Stöhr W, Rascher W and Dötsch J: Circulating resistin concentrations in children depend on renal function. Nephrol Dial Transplant. 21:107–112. 2006. View Article : Google Scholar : PubMed/NCBI
18	Ridker PM, Pare G, Parker A, et al: Loci related to metabolic-syndrome pathways including LEPR, HNF1A, IL6R, and GCKR associate with plasma C-reactive protein: the Women's Genome Health Study. Am J Hum Genet. 82:1185–1192. 2008. View Article : Google Scholar : PubMed/NCBI
19	Takeda A, Toda T, Shinohara S, Mogi Y and Matsui N: Factors contributing to higher hematocrit levels in hemodialysis patients not receiving recombinant human erythropoietin. Am J Kidney Dis. 40:104–109. 2002. View Article : Google Scholar : PubMed/NCBI
20	Di Iorio B, Cirillo M, Bellizzi V, Stellato D and De Santo NG: Campania Dialysis Registry Research Group: Prevalence and correlates of anemia and uncontrolled anemia in chronic hemodialysis patients - the Campania Dialysis Registry. Int J Artif Organs. 30:325–333. 2007.PubMed/NCBI
21	Locatelli F, Andrulli S, Memoli B, et al: Nutritional-inflammation status and resistance to erythropoietin therapy in haemodialysis patients. Nephrol Dial Transplant. 21:991–998. 2006. View Article : Google Scholar : PubMed/NCBI
22	Kotanko P, Thijssen S and Levin NW: Association between erythropoietin responsiveness and body composition in dialysis patients. Blood Purif. 26:82–89. 2008. View Article : Google Scholar : PubMed/NCBI